These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31557419)

  • 21. Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study.
    Galego O; Gouveia A; Batista S; Moura C; Machado E
    Neuroradiol J; 2015 Jun; 28(3):354-8. PubMed ID: 26246109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Focal White Matter Damage on Localized Subcortical Gray Matter Atrophy in Multiple Sclerosis: A 5-Year Study.
    Fuchs TA; Carolus K; Benedict RHB; Bergsland N; Ramasamy D; Jakimovski D; Weinstock-Guttman B; Kuceyeski A; Zivadinov R; Dwyer MG
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1480-1486. PubMed ID: 29976833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantifying the Susceptibility Variation of Normal-Appearing White Matter in Multiple Sclerosis by Quantitative Susceptibility Mapping.
    Chen W; Zhang Y; Mu K; Pan C; Gauthier SA; Zhu W; Wang Y
    AJR Am J Roentgenol; 2017 Oct; 209(4):889-894. PubMed ID: 28705068
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.
    Elliott C; Belachew S; Wolinsky JS; Hauser SL; Kappos L; Barkhof F; Bernasconi C; Fecker J; Model F; Wei W; Arnold DL
    Brain; 2019 Sep; 142(9):2787-2799. PubMed ID: 31497864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis.
    Steenwijk MD; Daams M; Pouwels PJ; J Balk L; Tewarie PK; Geurts JJ; Barkhof F; Vrenken H
    Hum Brain Mapp; 2015 May; 36(5):1796-807. PubMed ID: 25627545
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain tissue volumes and relaxation rates in multiple sclerosis: implications for cognitive impairment.
    Megna R; Alfano B; Lanzillo R; Costabile T; Comerci M; Vacca G; Carotenuto A; Moccia M; Servillo G; Prinster A; Brescia Morra V; Quarantelli M
    J Neurol; 2019 Feb; 266(2):361-368. PubMed ID: 30498912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Juxtacortical Lesions in Multiple Sclerosis: Assessment of Gray Matter Involvement Using Phase Difference-enhanced Imaging (PADRE).
    Futatsuya K; Kakeda S; Yoneda T; Ueda I; Watanabe K; Moriya J; Murakami Y; Ide S; Ogasawara A; Ohnari N; Okada K; Adachi H; Korogi Y
    Magn Reson Med Sci; 2016 Oct; 15(4):349-354. PubMed ID: 26841855
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of global and regional gray matter volume decrease in multiple sclerosis.
    Grothe M; Lotze M; Langner S; Dressel A
    J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New and enlarging white matter lesions adjacent to the ventricle system and thalamic atrophy are independently associated with lateral ventricular enlargement in multiple sclerosis.
    Sinnecker T; Ruberte E; Schädelin S; Canova V; Amann M; Naegelin Y; Penner IK; Müller J; Kuhle J; Décard B; Derfuss T; Kappos L; Granziera C; Wuerfel J; Magon S; Yaldizli Ö
    J Neurol; 2020 Jan; 267(1):192-202. PubMed ID: 31612322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients.
    Prins M; Dutta R; Baselmans B; Brevé JJ; Bol JG; Deckard SA; van der Valk P; Amor S; Trapp BD; de Vries HE; Drukarch B; van Dam AM
    Acta Neuropathol Commun; 2014 Aug; 2():98. PubMed ID: 25149422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of gadolinium contrast agent administration on automatic brain tissue classification of patients with multiple sclerosis.
    Warntjes JB; Tisell A; Landtblom AM; Lundberg P
    AJNR Am J Neuroradiol; 2014 Jul; 35(7):1330-6. PubMed ID: 24699093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Maranzano J; Rudko DA; Nakamura K; Cook S; Cadavid D; Wolansky L; Arnold DL; Narayanan S
    Neurology; 2017 Aug; 89(7):714-721. PubMed ID: 28724581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images.
    Jain S; Sima DM; Ribbens A; Cambron M; Maertens A; Van Hecke W; De Mey J; Barkhof F; Steenwijk MD; Daams M; Maes F; Van Huffel S; Vrenken H; Smeets D
    Neuroimage Clin; 2015; 8():367-75. PubMed ID: 26106562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalamic lesions in multiple sclerosis by 7T MRI: Clinical implications and relationship to cortical pathology.
    Harrison DM; Oh J; Roy S; Wood ET; Whetstone A; Seigo MA; Jones CK; Pham D; van Zijl P; Reich DS; Calabresi PA
    Mult Scler; 2015 Aug; 21(9):1139-50. PubMed ID: 25583851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-specific 3D FLAIR for enhanced visualization of brain white matter lesions in multiple sclerosis.
    Gabr RE; Pednekar AS; Govindarajan KA; Sun X; Riascos RF; Ramírez MG; Hasan KM; Lincoln JA; Nelson F; Wolinsky JS; Narayana PA
    J Magn Reson Imaging; 2017 Aug; 46(2):557-564. PubMed ID: 27869333
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of immunoablation and autologous hematopoietic stem cell transplantation on gray and white matter atrophy in multiple sclerosis.
    Lee H; Nakamura K; Narayanan S; Brown R; Chen J; Atkins HL; Freedman MS; Arnold DL
    Mult Scler; 2018 Jul; 24(8):1055-1066. PubMed ID: 28617152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H-magnetic resonance spectroscopy.
    Kapeller P; Ropele S; Enzinger C; Lahousen T; Strasser-Fuchs S; Schmidt R; Fazekas F
    J Neurol; 2005 Oct; 252(10):1229-34. PubMed ID: 15895306
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How relevant are cerebral white matter lesions in the D313Y variant of the α-galactosidase A gene? Neurological, cardiological, laboratory, and MRI data of 21 patients within a follow-up of 3 years.
    Strunk D; Becker J; Veltkamp R; Meuth SG; Bauer P; Böttcher T; Rolfs A; Schwitalla JC; Kraemer M
    Neurol Sci; 2023 Apr; 44(4):1375-1381. PubMed ID: 36456878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis.
    Schlaeger R; Papinutto N; Zhu AH; Lobach IV; Bevan CJ; Bucci M; Castellano A; Gelfand JM; Graves JS; Green AJ; Jordan KM; Keshavan A; Panara V; Stern WA; von Büdingen HC; Waubant E; Goodin DS; Cree BA; Hauser SL; Henry RG
    JAMA Neurol; 2015 Aug; 72(8):897-904. PubMed ID: 26053119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cortical and Subcortical Morphometric and Iron Changes in Relapsing-Remitting Multiple Sclerosis and Their Association with White Matter T2 Lesion Load : A 3-Tesla Magnetic Resonance Imaging Study.
    Al-Radaideh A; Athamneh I; Alabadi H; Hbahbih M
    Clin Neuroradiol; 2019 Mar; 29(1):51-64. PubMed ID: 29299614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.